pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
112
stories
May 12, 26
STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
stat
May 12, 26
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
biopharma dive
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 12, 26
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
endpoints
May 12, 26
STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
stat
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
May 7, 26
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
onclive
May 6, 26
Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
onclive
May 6, 26
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
biopharma dive
May 5, 26
Cytokinetics heart drug scores in closely watched trial
biopharma dive
May 5, 26
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
endpoints
May 4, 26
UCB to acquire maker of antibody treatments for autoimmune diseases
stat
May 4, 26
UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
biopharma dive
May 2, 26
Bristol Myers’ pivotal year; Should AI be swinging bigger?; and more
endpoints
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
Apr 30, 26
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
endpoints
Apr 30, 26
STAT+: Five-way obesity drug is super effective — in mice
stat
Apr 30, 26
Analysts focus on three programs in big year for Bristol Myers
endpoints
Apr 30, 26
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
biopharma dive
Apr 29, 26
Bristol Myers reaches a crossroads as a make-or-break year takes shape
endpoints
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
← prev
page 4 of 4
next →
